Human Prothrombin Complex Market

The human prothrombin complex market was valued at USD10,636.7Mn by 2019. According to the latest statistics provided by the National Hemophilia Foundation (NHF), approximately 400,000 people worldwide are suffering from Hemophilia. Additionally, the technological advancement in the development of human prothrombin complex from human plasma or recombinant biotechnology will further propel the market growth.

The human prothrombin complex is also popularly known as factor IX complex, but it comprises of blood clotting factors such as II, VII, IX, and X. It is available lyophilized concentrate for reconstitution in dosage strengths of 500 units/vial, 1000 units/vial, etc. It is enlisted in the World Health Organization (WHO) list of essential medicines for treating bleeding disorders in patients across all age groups. Proper dosing calculation needs to be maintained in order to negate severe adverse events such as thromboembolic events, headache, hypotension, nausea, vomiting, etc.

The major segments related to the human prothrombin complex market are:

By Clinical Application (2017–2027; US$ Mn)

Vitamin K Antagonist Reversal

Inherited Bleeding Disorders

Others

By End Users (2017–2027; US$ Mn)

Hospitals

Clinics

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global human prothrombin complex market
• The overall segmentation of the human prothrombin complex market, by clinical application, end-users, and geography is minutely studied. Vitamin K antagonist reversal and hospitals are dominating the clinical application and end-user segments respectively
• Increasing demand for vitamin K antagonist reversal therapy in patients receiving blood-thinning medication
• Significant increase in the number of patients suffering from inherited bleeding disorders further increases the demand for human prothrombin complex market

Report gist?

• The study of the global human prothrombin complex market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and end-users categorization of the same at geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
• The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical companies engaged in manufacturing and marketing of human prothrombin complex for vitamin k antagonist reversal in patients receiving blood-thinning drugs
• The report will benefit researchers engaged in the novel drug development for the treatment of inherited bleeding disorders
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to human prothrombin complex market
• Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies

Segment Analysis

Vitamin K antagonist reversal is leading the clinical application segment for the human prothrombin complex market. Blood-thinning drugs used to treat venous thromboembolism, pulmonary embolism often results in side effects such as hemorrhage, intracranial bleeding, etc., which thereby increases the demand for vitamin K antagonist reversal therapy. Inherited bleeding disorders will be the fastest-growing segment during the forecast period. The constant increase in the number of patients suffering from Hemophilia A, B, Von Willebrand disease, etc. drives the human prothrombin complex market growth.

Hospitals are dominating the end-users segment for human prothrombin complex market. Accurate screening and followed by immediate adoption of treatment regimen associated with bleeding disorders are the primary factors responsible for its market dominance. It serves as the first point of contact for patients residing in remote locations. Clinics are garnering huge traction in the developing countries owing to a proactive role adopted by government healthcare agencies to establish clinics in order to reduce the healthcare burden associated with government primary healthcare centers.

North America is the clear leader in the geography segment for the human prothrombin complex market. Rising prevalence of cardiovascular patients receiving blood-thinning drugs and a constant rise in vitamin k deficiency reported in the adolescent population increases the demand for human prothrombin complex in the North American region. Affordable reimbursement scenario and presence of key players such as Baxter AG, Octapharma AG, CSL Behring, Shire, Plc., etc. further accentuate the market growth in the region. Europe is currently in the second position in the regional segment for the human prothrombin complex on account of the rising prevalence of inherited bleeding disorders across all age groups. As per the latest research citings presented by the European Hematology Network (EUHANET), the prevalence rate of inherited bleeding disorders associated with Hemophilia A and B is 1 in 10,000 and 1 in 50,000 population respectively. Asia Pacific is keen to register rampant market growth in the near future on account of developing healthcare infrastructure and lucrative market opportunities for the western pharmaceutical giants to establish retail outlets and subsidiaries in the Asia Pacific region.